| Trial ID: | L5394 |
| Source ID: | NCT03867500
|
| Associated Drug: |
Niacin
|
| Title: |
Effects of Niacin on Intramyocellular Fatty Acid Trafficking in Upper Body Obesity and Type 2 Diabetes Mellitus
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT03867500/results
|
| Conditions: |
Type 2 Diabetes Mellitus|Obesity
|
| Interventions: |
DRUG: Niacin|DRUG: Saline
|
| Outcome Measures: |
Primary: Glucose Infusion Rate, Glucose infusion rates will be measured in upper body obese and type 2 diabetic volunteers using hyperinsulinemic, euglycemic clamp under saline control conditions and during an intravenous infusion of niacin. The hyperinsulinemic-euglycemic clamp is a method used to measure insulin sensitivity. Plasma insulin concentration is acutely raised and maintained at \~40-80 μU/ml (microunits per milliliter) by continuous insulin infusion. During the clamp, the plasma glucose concentration was held constant at normal blood sugar level. The glucose infusion rate over the last hour of the insulin infusion is the net effect of insulin on whole-body glucose metabolism. This rate serves as a measure of tissue insulin sensitivity. The hyperinsulinemic-euglycemic clamp assesses how sensitive your tissues are to insulin., 18 hours |
|
| Sponsor/Collaborators: |
Sponsor: Mayo Clinic | Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
|
| Gender: |
ALL
|
| Age: |
ADULT
|
| Phases: |
EARLY_PHASE1
|
| Enrollment: |
12
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: BASIC_SCIENCE
|
| Start Date: |
2018-11-01
|
| Completion Date: |
2021-12-22
|
| Results First Posted: |
2024-08-06
|
| Last Update Posted: |
2025-01-17
|
| Locations: |
Mayo Clinic in Rochester, Rochester, Minnesota, 55905, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT03867500
|
